Related Experiment Video
Updated: Aug 13, 2026
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Discovery of two novel, small-molecule inhibitors of DNA methylation
Pawel Siedlecki1, Regine Garcia Boy, Tanja Musch
1Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawinskiego 5a, 02-106 Warsaw, Poland.
Abstract:
DNA methyltransferases are promising targets for cancer therapy. In many cancer cells promoters of tumor suppressor genes are hypermethylated, which results in gene inactivation. It has been shown that DNA methyltransferase inhibitors can suppress tumor growth and have significant therapeutic value. However, the established inhibitors are limited in their application due to their substantial cytotoxicity. To discover novel compounds for the inhibition of human DNA methyltransferases, we have screened a set of small molecules available from the NCI database. Using a 3-dimensional model of the human DNA methyltransferase 1 and a modified docking and scoring procedure, we have identified a small list of molecules with high affinities for the active site of the enzyme. The two highest scoring structures were found to inhibit DNA methyltransferase activity in vitro and in vivo. The newly discovered inhibitors validate our screening procedure and also provide a useful basis for further rational drug development.
Insights
Novel DNA methyltransferase inhibitors were identified for cancer therapy. These compounds show promise in suppressing tumor growth with reduced cytotoxicity compared to existing treatments.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- DNA methyltransferases (DNMTs) are crucial in gene regulation, and their aberrant activity, particularly hypermethylation of tumor suppressor genes, is a hallmark of cancer.
- DNMT inhibitors offer therapeutic potential by reactivating silenced tumor suppressor genes, but current options face limitations due to significant cytotoxicity.
- Developing novel, less toxic DNMT inhibitors is essential for advancing cancer treatment strategies.
Purpose of the Study:
- To identify novel small molecules that inhibit human DNA methyltransferase 1 (DNMT1) activity.
- To discover compounds with high affinity for the DNMT1 active site, suitable for further rational drug development.
- To overcome the cytotoxicity limitations associated with established DNMT inhibitors.
Main Methods:
- Screening of small molecules from the National Cancer Institute (NCI) database.
- Utilizing a 3-dimensional model of human DNMT1 for structure-based virtual screening.
- Employing a modified docking and scoring procedure to predict high-affinity binders.
- In vitro and in vivo validation of the inhibitory activity of top-scoring compounds.
Main Results:
- A small list of molecules with high predicted affinities for the DNMT1 active site was identified.
- Two highest-scoring compounds demonstrated significant inhibition of DNMT1 activity in both in vitro and in vivo assays.
- The identified compounds represent promising candidates for further preclinical development.
Conclusions:
- The virtual screening procedure successfully identified novel DNMT inhibitors.
- The newly discovered compounds exhibit potent DNMT inhibitory activity and validate the screening approach.
- These findings provide a strong foundation for the rational design and development of next-generation cancer therapeutics targeting DNMTs.
Related Concept Videos
01:28Inhibitors of Bacterial DNA Synthesis
01:17Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
01:37Epigenetic Regulation
X-chromosome...